查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球巨細胞病毒治療市場
市場調查報告書
商品編碼
1311871

2023-2030年全球巨細胞病毒治療市場

Global Cytomegalovirus Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

在預測期內（2023-2030年），全球巨細胞病毒（CMV）治療市場預計將以5.8%的年複合成長率成長。巨細胞病毒視網膜炎和先天性巨細胞病毒感染發病率的上升，以及對這些疾病的治療和診斷意識的提高，是推動巨細胞病毒治療市場成長的關鍵因素。例如，根據美國疾病預防控制中心（CDC）的最新資料，截至2022年5月，美國每年約有150 名嬰兒在出生時感染CMV，其中少數嬰兒會出現長期健康問題。嬰兒感染CMV 後產生的干擾素反應減弱，而成人感染CMV 後則會產生類似的反應。

根據同一資料來源，妊娠期也有CMV 感染和CMV 感染再活化風險的報導，也可能導致先天性CMV 感染。因此，疾病負擔的增加預計將產生對有效治療方案的需求，推動CMV 治療市場的成長。為開發新藥而進行的臨床試驗研究日益增多，這可能會推動全球市場的成長。

目 錄

第1章：報告摘要

  • 行業現狀分析與成長潛力展望
  • 研究方法和工具
  • 市場細分
    • 按細分市場
    • 按地區

第2章：市場概述與洞察

  • 報告範圍
  • 分析師洞察與當前市場趨勢
    • 主要結論
    • 建議
    • 結論

第3章：競爭格局

  • 主要公司分析
  • F. Hoffmann-La Roche Ltd.
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Gilead Sciences, Inc.
    • 公司概況
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Teva Canada Ltd.
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 關鍵戰略分析

第4章：市場細分

  • 按藥物類型分類的全球巨細胞病毒治療市場
    • Cidofovir
    • Foscarnet
    • Valganciclovir
    • Ganciclovir
  • 按應用分類的全球巨細胞病毒治療市場
    • 幹細胞移植
    • 器官移植
    • 先天性巨細胞病毒感染
    • 其他應用
  • 按銷售管道分類的全球巨細胞病毒治療市場
    • 醫院藥房
    • 零售藥店
    • 電子商務

第5章：地區分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第6章：公司簡介

  • AiCuris Anti-infective Cures GmbH
  • Chimerix, Inc.
  • Clinigen Group PLC
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi Canada
  • Genentech Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Mylan NV
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals Inc
  • Thermo Fisher Scientific, Inc.
  • Vical, Inc.
  • ViroPharma, Inc.
Product Code: OMR2027352

Title: Global Cytomegalovirus Treatment Market Size, Share & Trends Analysis Report by Drug Type (Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir), By Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, and Other Application), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, and E-commerce), Forecast Period (2023-2030).

The global cytomegalovirus (CMV) treatment market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The rising prevalence of CMV retinitis and congenital CMV infection, along with increasing initiatives to create awareness regarding treatments and diagnosis of these conditions is a key factor driving the growth of the CMV treatment market. For instance, as per the updated CDC data, as of May 2022, in the US, around 150 infants are born with CMV infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult.

As per the same source, CMV infection and the risk of reactivation of CMV infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is anticipated to create the demand for effective treatment options, thereby driving the CMV treatment market growth. The increasing clinical trial studies for the development of new drugs are likely to drive the growth of the global market.

In April 2022, the researchers have developed a calculator external link to estimate the risk that CMV infection will pass to a fetus during pregnancy. This congenital CMV infection occurs in about 20.0% to 40.0% of cases of primary maternal CMV infection. By offering a noninvasive way to predict the chance of congenital CMV based on individual characteristics, the calculator may support healthcare provider to counsel pregnant people with CMV. Such developments are anticipated to lower the infection rate in infants.

Segmental Outlook

The global cytomegalovirus treatment market is segmented on the drug type, application, and distribution channel. Based on the drug type, the market is sub-segmented into Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir. Based on the application, the market is sub-segmented into stem cell transplantation, organ transplantation, congenital CMV infection, and other application. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and E-commerce.

Regional Outlook

The global cytomegalovirus treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of key market players along with high healthcare expenditure. The increasing incidences of cytomegalovirus infections along with increasing awareness among consumers also play a crucial role in the regional market growth. For instance, the article published by the National Institute of Neurological Disorders and Stroke (NINDS) in July 2022 mentioned that CMV infected about 50.0% to 80.0% of adults by the age of 40 and is one of the most congenital infections in the US annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. Such an increased incidence of CMV among the North American population to create higher demand for effective treatment thereby is driving the growth of the market.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Cytomegalovirus Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing federal funding for stem cell research, which is one of the core application areas of CMV drugs. In India, the Department of Biotechnology (DBT) has supported projects for basic biology of stem cells; early and late translational research; developing gene editing technology for potential therapeutic applications and creation of animal models for various human diseases. As of 2021, the funds released by the DBT during the last three years and the current year in this area is $89.6 million.

Market Players Outlook

The major companies serving the cytomegalovirus treatment market include: F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies including funding for R&D, and new drug development, to stay competitive in the market. For instance, in September 2022, Takeda announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cytomegalovirus treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Gilead Sciences, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Canada Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cytomegalovirus Treatment Market by Drug Type
    • 4.1.1. Cidofovir
    • 4.1.2. Foscarnet
    • 4.1.3. Valganciclovir
    • 4.1.4. Ganciclovir
  • 4.2. Global Cytomegalovirus Treatment Markey by Application
    • 4.2.1. Stem Cell Transplantation
    • 4.2.2. Organ Transplantation
    • 4.2.3. Congenital CMV Infection
    • 4.2.4. Other Application
  • 4.3. Global Cytomegalovirus Treatment Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. E-Commerce

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AiCuris Anti-infective Cures GmbH
  • 6.2. Chimerix, Inc.
  • 6.3. Clinigen Group PLC
  • 6.4. F. Hoffmann-La Roche AG
  • 6.5. Fresenius Kabi Canada
  • 6.6. Genentech Inc.
  • 6.7. Gilead Sciences, Inc.
  • 6.8. GlaxoSmithKline plc
  • 6.9. Merck & Co., Inc.
  • 6.10. Moderna, Inc.
  • 6.11. Mylan N.V
  • 6.12. Pfizer Inc.
  • 6.13. Takeda Pharmaceuticals
  • 6.14. Teva Pharmaceuticals Inc
  • 6.15. Thermo Fisher Scientific, Inc.
  • 6.16. Vical, Inc.
  • 6.17. ViroPharma, Inc.

LIST OF TABLES

  • 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL CIDOFOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL FOSCARNET FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL VALGANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL GANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR STEM CELL TRANSPLANTATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR ORGAN TRANSPLANTATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR CONGENITAL CMV INFECTION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 10. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR OTHER APPLICATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 12. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 14. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR E-COMMERCE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL CIDOFOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL FOSCARNET FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL VALGANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL GANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 ($ MILLION)
  • 7. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR STEM CELL TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR ORGAN TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR CONGENITAL CMV INFECTION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR OTHER APPLICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 12. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR RETAIL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR E-COMMERCE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)